KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Inventory (2017 - 2025)

Aquestive Therapeutics has reported Inventory over the past 9 years, most recently at $6.2 million for Q4 2025.

  • Quarterly results put Inventory at $6.2 million for Q4 2025, up 2.07% from a year ago — trailing twelve months through Dec 2025 was $6.2 million (up 2.07% YoY), and the annual figure for FY2025 was $6.2 million, up 2.07%.
  • Inventory for Q4 2025 was $6.2 million at Aquestive Therapeutics, down from $7.9 million in the prior quarter.
  • Over the last five years, Inventory for AQST hit a ceiling of $8.1 million in Q2 2025 and a floor of $2.8 million in Q1 2021.
  • Median Inventory over the past 5 years was $6.4 million (2022), compared with a mean of $5.9 million.
  • Biggest five-year swings in Inventory: dropped 11.69% in 2021 and later soared 134.89% in 2022.
  • Aquestive Therapeutics' Inventory stood at $4.0 million in 2021, then surged by 43.14% to $5.8 million in 2022, then rose by 17.11% to $6.8 million in 2023, then decreased by 10.71% to $6.0 million in 2024, then increased by 2.07% to $6.2 million in 2025.
  • The last three reported values for Inventory were $6.2 million (Q4 2025), $7.9 million (Q3 2025), and $8.1 million (Q2 2025) per Business Quant data.